Revista española de salud pública
-
Rev. Esp. Salud Publica · May 2008
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies].
Much biomedical research is observational. The reporting of such research is often inadequate, which hampers the assessment of its strengths and weaknesses and of a study's generalisability. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) initiative developed recommendations on what should be included in an accurate and complete report of an observational study. ⋯ The workshop and the subsequent iterative process of consultation and revision resulted in a checklist of 22 items (the STROBE statement) that relate to the title, abstract, introduction, methods, results, and discussion sections of articles. 18 items are common to all three study designs and four are specific for cohort, case-control, or cross-sectional studies. A detailed explanation and elaboration document is published separately and is freely available on the websites of PLoS Medicine, Annals of Internal Medicine, and Epidemiology. We hope that the STROBE statement will contribute to improving the quality of reporting of observational studies.
-
Rev. Esp. Salud Publica · Nov 2007
Comparative Study[Design and validation of a questionnaire of the hospital outpatient clinics in Madrid, Spain, 2006].
In order to improve the quality of health care it is necessary to know the point of view of the patients through satisfaction surveys. Satisfaction surveys need some psychometric properties to guarantee its reliability and validity. The aim of this paper is to design and to validate a questionnaire to determine the satisfaction of patients of the hospital outpatient clinics. ⋯ Our questionnaire has enough psychometric properties to be considered an useful and feasible tool to measure the satisfaction of patients of the hospital outpatient clinics.
-
Rev. Esp. Salud Publica · Nov 2006
Review[Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests].
The benefits of aspirin treatment in reducing the risk of myocardial infarction, cerebrovascular accidents and vascular death is well-documented among individuals having prior cardiovascular disease, including the subgroup with diabetes mellitus. The role of aspirin in primary prevention is less clear and debatable: the results of the clinical trials currently available are not consistent, although the meta-analyses are favorable in some aspects. ⋯ Despite this fact, in 1997, the American Diabetes Association and more recently other scientific societies (including several Spanish societies) have been recommending the use of aspirin in low doses in primary prevention in all type 1 or type 2 diabetic patients over 40 years of age and in all those within the 21-40 age range having any other cardiovascular risk factor in addition to diabetes (family history of vascular disease, hypertension, smoking, dyslipidemia or albuminuria). This study reviews the findings of the randomized, controlled clinical trials on primary cardiovascular prevention with aspirin, on which the official American Diabetes Association guidelines might be based, the conclusion being reached that there is not currently sufficient scientific evidence to uphold these guidelines.